Co-Founding CEO (Metabolic & Inflammation Therapies)
NLC Health Ventures
Remote, Worldwide
Co-Founding CEO (Metabolic & Inflammation Therapies)
Location: Remote Commitment: Part-time to start, with greater time commitment expected as the company scales Compensation : Equity only, transitioning to salary after fundraising Start Date : ASAP preferred, Q4 2026 at the latest Seniority : Co-founder / Leadership
About the Company
This startup is developing a new kind of small molecule to treat diabetic kidney disease (DKD) and other metabolic diseases.
Their approach is different from existing treatments: instead of managing symptoms (like blood sugar or blood pressure), their drug targets the root cause: a molecular signal inside cells that triggers inflammation and scarring in the kidneys.
Their lead drug, INT-101, is first-in-class and acts by blocking a specific interaction between two proteins (RAGE and DIAPH1). Blocking this interaction mitigates the downstream effects that lead to kidney inflammation and fibrosis. As a result, it has the potential to restore kidney function, not just slow the damage. No other current therapies have this disease-modifying effect.
Built on Professor Ann Marie Schmidt's pioneering RAGE biology research at NYU, the platform shows...
Sourced from Himalayas
This page is a short summary. The full posting and the application are at the source.